Novitas says Pacific Edge’s CxBladder tests are ‘not payable’

Novitas says Pacific Edge’s CxBladder tests are ‘not payable’
The company can continue to apply for renewed coverage. (Image: Pacific Edge)
Rebecca Howard
The long-awaited draft Local Coverage Determination from Novitas is not good news for Pacific Edge’s US business. According to the determination (LCD), “CxBladder tests are not reasonable and necessary to support positive outcomes in the management of bladder cancer and, therefore, are not payable”.In June 2023, Pacific Edge confirmed that the LCD from Novitas — its Medicare administrative contractor — meant its flagship Cxbladder test for bladder cancer didn’t meet the threshold required for coverage un...

More Markets

NZ sharemarket ends lower, spike in oil prices
Markets Market Close

NZ sharemarket ends lower, spike in oil prices

Australian, Hong Kong and Japanese share markets were all down after the attack.

Jamie Gray 13 Jun 2025
Bremworth wins $2m Kāinga Ora wool carpet contract
Primary Sector

Bremworth wins $2m Kāinga Ora wool carpet contract

The NZX-listed carpet market says the contract is of huge strategic value.

Staff reporters 13 Jun 2025
New Meridian boss warns market intervention comes with high risk
Markets

New Meridian boss warns market intervention comes with high risk

Mike Roan says electricity prices will come down in his term as CEO.

Ian Llewellyn 13 Jun 2025
NZ sharemarket flat amid global fears of Iran strike
Markets Market Close

NZ sharemarket flat amid global fears of Iran strike

NZ investors are looking with concern at rumblings in the Middle East.

Tom Raynel 12 Jun 2025